Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial

Clinical article

Restricted access

Object

Cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH) is a major cause of subsequent morbidity and mortality. Cilostazol, a selective inhibitor of phosphodiesterase 3, may attenuate cerebral vasospasm because of its antiplatelet and vasodilatory effects. A multicenter prospective randomized trial was conducted to investigate the effect of cilostazol on cerebral vasospasm.

Methods

Patients admitted with SAH caused by a ruptured anterior circulation aneurysm who were in Hunt and Kosnik Grades I to IV and were treated by clipping within 72 hours of SAH onset were enrolled at 7 neurosurgical sites in Japan. These patients were assigned to one of 2 groups: the usual therapy group (control group) or the add-on 100 mg cilostazol twice daily group (cilostazol group). The group assignments were done by a computer-generated randomization sequence. The primary study end point was the onset of symptomatic vasospasm. Secondary end points were the onset of angiographic vasospasm and new cerebral infarctions related to cerebral vasospasm, clinical outcome as assessed by the modified Rankin scale, and length of hospitalization. All end points were assessed for the intention-to-treat population.

Results

Between November 2009 and December 2010, 114 patients with SAH were treated by clipping within 72 hours from the onset of SAH and were screened. Five patients were excluded because no consent was given. Thus, 109 patients were randomly assigned to the cilostazol group (n = 54) or the control group (n = 55). Symptomatic vasospasm occurred in 13% (n = 7) of the cilostazol group and in 40% (n = 22) of the control group (p = 0.0021, Fisher exact test). The incidence of angiographic vasospasm was significantly lower in the cilostazol group than in the control group (50% vs 77%; p = 0.0055, Fisher exact test). Multiple logistic analyses demonstrated that nonuse of cilostazol is an independent factor for symptomatic and angiographic vasospasm. The incidence of new cerebral infarctions was also significantly lower in the cilostazol group than in the control group (11% vs 29%; p = 0.0304, Fisher exact test). Clinical outcomes at 1, 3, and 6 months after SAH in the cilostazol group were better than those in the control group, although a significant difference was not shown. There was also no significant difference in the length of hospitalization between the groups. No severe adverse event occurred during the study period.

Conclusions

Oral administration of cilostazol is effective in preventing cerebral vasospasm with a low risk of severe adverse events. Clinical trial registration no. UMIN000004347, University Hospital Medical Information Network Clinical Trials Registry.

Abbreviations used in this paper:CTA = CT angiography; DSA = digital subtraction angiography; ICA = internal carotid artery; MCA = middle cerebral artery; mRS = modified Rankin Scale; SAH = subarachnoid hemorrhage.
Article Information

Contributor Notes

Address correspondence to: Hiroyuki Kinouchi, M.D., Ph.D., Department of Neurosurgery, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi 409-3898, Japan. email: hkinouchi@yamanashi.ac.jp.Please include this information when citing this paper: published online October 5, 2012; DOI: 10.3171/2012.9.JNS12492.
Headings
References
  • 1

    Bederson JBConnolly ES JrBatjer HHDacey RGDion JEDiringer MN: Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 40:99410252009

    • Search Google Scholar
    • Export Citation
  • 2

    Birk SKruuse CPetersen KAJonassen OTfelt-Hansen POlesen J: The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 24:135213582004

    • Search Google Scholar
    • Export Citation
  • 3

    Charpentier CAudibert GGuillemin FCivit TDucrocq XBracard S: Multivariate analysis of predictors of cerebral vasospasm occurrence after aneurysmal subarachnoid hemorrhage. Stroke 30:140214081999

    • Search Google Scholar
    • Export Citation
  • 4

    Chaudhary SRKo NDillon WPYu MBLiu SCriqui GI: Prospective evaluation of multidetector-row CT angiography for the diagnosis of vasospasm following subarachnoid hemorrhage: a comparison with digital subtraction angiography. Cerebrovasc Dis 25:1441502008

    • Search Google Scholar
    • Export Citation
  • 5

    Dankbaar JWRijsdijk Mvan der Schaaf ICVelthuis BKWermer MJHRinkel GJE: Relationship between vasospasm, cerebral perfusion, and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Neuroradiology 51:8138192009

    • Search Google Scholar
    • Export Citation
  • 6

    Ecker ARiemenschneider PA: Arteriographic demonstration of spasm of the intracranial arteries, with special reference to saccular arterial aneurysms. J Neurosurg 8:6606671951

    • Search Google Scholar
    • Export Citation
  • 7

    Eskridge JMMcAuliffe WSong JKDeliganis AVNewell DWLewis DH: Balloon angioplasty for the treatment of vasospasm: results of first 50 cases. Neurosurgery 42:5105171998

    • Search Google Scholar
    • Export Citation
  • 8

    Findlay JMKassell NFWeir BKHaley EC JrKongable GGermanson T: A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery 37:1681781995

    • Search Google Scholar
    • Export Citation
  • 9

    Findlay JMWeir BKKassell NFDisney LBGrace MG: Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhage. J Neurosurg 75:1811881991

    • Search Google Scholar
    • Export Citation
  • 10

    Fisher CMKistler JPDavis JM: Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 6:191980

    • Search Google Scholar
    • Export Citation
  • 11

    Frontera JAClaassen JSchmidt JMWartenberg KETemes RConnolly ES Jr: Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified fisher scale. Neurosurgery 59:21272006

    • Search Google Scholar
    • Export Citation
  • 12

    Frontera JAFernandez ASchmidt JMClaassen JWartenberg KEBadjatia N: Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition?. Stroke 40:196319682009

    • Search Google Scholar
    • Export Citation
  • 13

    Gotoh FTohgi HHirai STerashi AFukuuchi YOtomo E: Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9:1471572000

    • Search Google Scholar
    • Export Citation
  • 14

    Haley EC JrKassell NFTorner JC: A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 78:5375471993

    • Search Google Scholar
    • Export Citation
  • 15

    Haley EC JrKassell NFTorner JCTruskowski LLGermanson TP: A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 80:7887961994

    • Search Google Scholar
    • Export Citation
  • 16

    Hashimoto AMiyakoda GHirose YMori T: Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 189:3503572006

    • Search Google Scholar
    • Export Citation
  • 17

    Hirashima YKurimoto MHori EOrigasa HEndo S: Lower incidence of symptomatic vasospasm after subarachnoid hemorrhage owing to ruptured vertebrobasilar aneurysms. Neurosurgery 57:111011162005

    • Search Google Scholar
    • Export Citation
  • 18

    Hunt WEKosnik EJ: Timing and perioperative care in intracranial aneurysm surgery. Clin Neurosurg 21:79891974

  • 19

    Ito HFukunaga MSuzuki HMiyakoda GIshikawa MYabuuchi Y: Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging. Neurobiol Dis 32:1571612008

    • Search Google Scholar
    • Export Citation
  • 20

    Kambayashi JLiu YSun BShakur YYoshitake MCzerwiec F: Cilostazol as a unique antithrombotic agent. Curr Pharm Des 9:228923022003

    • Search Google Scholar
    • Export Citation
  • 21

    Kassell NFTorner JCHaley EC JrJane JAAdams HPKongable GL: The international cooperative study on the timing of aneurysm surgery. Part 1: overall management results. J Neurosurg 73:18361990

    • Search Google Scholar
    • Export Citation
  • 22

    Kinouchi HOgasawara KShimizu HMizoi KYoshimoto T: Prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage by intraoperative cisternal fibrinolysis using tissue-type plasminogen activator combined with continuous cisternal drainage. Neurol Med Chir (Tokyo) 44:5695772004

    • Search Google Scholar
    • Export Citation
  • 23

    Mizoi KYoshimoto TTakahashi AFujiwara SKoshu KSugawara T: Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator. J Neurosurg 78:4304371993

    • Search Google Scholar
    • Export Citation
  • 24

    Molyneux AJKerr RSBirks JRamzi NYarnold JSneade M: Risk of recurrent subarachnoid haemorrhage, death, or dependence and standardised mortality ratios after clipping or coiling of an intracranial aneurysm in the International Subarachnoid Aneurysm Trial (ISAT): long-term follow-up. Lancet Neurol 8:4274332009

    • Search Google Scholar
    • Export Citation
  • 25

    Musahl CHenkes HVajda ZCoburger JHopf N: Continuous local intra-arterial nimodipine administration in severe symptomatic vasospasm after subarachnoid hemorrhage. Neurosurgery 68:154115472011

    • Search Google Scholar
    • Export Citation
  • 26

    Ogihara KZubkov AYBernanke DHLewis AIParent ADZhang JH: Oxyhemoglobin-induced apoptosis in cultured endothelial cells. J Neurosurg 91:4594651999

    • Search Google Scholar
    • Export Citation
  • 27

    Okiyama KMachida TFujikawa ANagano OAoyagi KNomura R: [Evaluation of cerebral vasospasm after subarachnoid hemorrhage based on serial 3D-CTA findings.]. Surg Cereb Stroke 39:7132011. (Jpn)

    • Search Google Scholar
    • Export Citation
  • 28

    Origitano TCWascher TMReichman OHAnderson DE: Sustained increased cerebral blood flow with prophylactic hypertensive hypervolemic hemodilution (“triple-H” therapy) after subarachnoid hemorrhage. Neurosurgery 27:7297401990

    • Search Google Scholar
    • Export Citation
  • 29

    Otawara YOgasawara KOgawa ASasaki MTakahashi K: Evaluation of vasospasm after subarachnoid hemorrhage by use of multislice computed tomographic angiography. Neurosurgery 51:9399432002

    • Search Google Scholar
    • Export Citation
  • 30

    Pickard JDMurray GDIllingworth RShaw MDTeasdale GMFoy PM: Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 298:6366421989

    • Search Google Scholar
    • Export Citation
  • 31

    Rankin J: Cerebral vascular accidents in patients over the age of 60. II Prognosis. Scott Med J 2:2002151957

  • 32

    Sasaki TKodama NKawakami MSato MAsari JSakurai Y: Urokinase cisternal irrigation therapy for prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage: a study of urokinase concentration and the fibrinolytic system. Stroke 31:125612622000

    • Search Google Scholar
    • Export Citation
  • 33

    Sawada MHashimoto NTsukahara TNishi SKaku YYoshimura S: Effectiveness of intra-arterially infused papaverine solutions of various concentrations for the treatment of cerebral vasospasm. Acta Neurochir (Wien) 139:7067111997

    • Search Google Scholar
    • Export Citation
  • 34

    Shibuya MSuzuki YSugita KSaito ISasaki TTakakura K: Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 76:5715771992

    • Search Google Scholar
    • Export Citation
  • 35

    Shinohara YKatayama YUchiyama SYamaguchi THanda SMatsuoka K: Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 9:9599682010

    • Search Google Scholar
    • Export Citation
  • 36

    Shinohara YOgawa ASuziki NKatayama YKimura A: Treatment of delayed cerebral vasospasm. Japanese Guidelines for the Management of Stroke 2009 TokyoKyowa Kikaku2009. 211213(Jpn)

    • Search Google Scholar
    • Export Citation
  • 37

    Shinohara YYamaguchi T: Outline of the Japanese Guidelines for the Management of Stroke 2004 and subsequent revision. Int J Stroke 3:55622008

    • Search Google Scholar
    • Export Citation
  • 38

    Solenski NJHaley EC JrKassell NFKongable GGermanson TTruskowski L: Medical complications of aneurysmal subarachnoid hemorrhage: a report of the multicenter, cooperative aneurysm study. Participants of the Multicenter Cooperative Aneurysm Study. Crit Care Med 23:100710171995

    • Search Google Scholar
    • Export Citation
  • 39

    Suzuki JKomatsu SSato TSakurai Y: Correlation between CT findings and subsequent development of cerebral infarction due to vasospasm in subarachnoid haemorrhage. Acta Neurochir (Wien) 55:63701980

    • Search Google Scholar
    • Export Citation
  • 40

    Suzuki SSayama TNakamura TNishimura HOhta MInoue T: Cilostazol improves outcome after subarachnoid hemorrhage: a preliminary report. Cerebrovasc Dis 32:89932011

    • Search Google Scholar
    • Export Citation
  • 41

    Tachibana EHarada TShibuya MSaito KTakayasu MSuzuki Y: Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien) 141:13191999

    • Search Google Scholar
    • Export Citation
  • 42

    Teasdale GJennett B: Assessment of coma and impaired consciousness. A practical scale. Lancet 2:81841974

  • 43

    Vajkoczy PMeyer BWeidauer SRaabe AThome CRingel F: Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 103:9172005

    • Search Google Scholar
    • Export Citation
  • 44

    Vergouwen MDVermeulen MCoert BAStroes ESRoos YB: Microthrombosis after aneurysmal subarachnoid hemorrhage: an additional explanation for delayed cerebral ischemia. J Cereb Blood Flow Metab 28:176117702008

    • Search Google Scholar
    • Export Citation
  • 45

    Voldby BEnevoldsen EMJensen FT: Regional CBF, intraventricular pressure, and cerebral metabolism in patients with ruptured intracranial aneurysms. J Neurosurg 62:48581985

    • Search Google Scholar
    • Export Citation
  • 46

    Weidauer SLanfermann HRaabe AZanella FSeifert VBeck J: Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after aneurysmal subarachnoid hemorrhage: a prospective MRI and DSA study. Stroke 38:183118362007

    • Search Google Scholar
    • Export Citation
  • 47

    Wilhite DBComerota AJSchmieder FAThrom RCGaughan JPRao AK: Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 38:7107132003

    • Search Google Scholar
    • Export Citation
  • 48

    Yamaguchi-Okada MNishizawa SMizutani ANamba H: Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model. Cerebrovasc Dis 28:1351422009

    • Search Google Scholar
    • Export Citation
  • 49

    Yasunaga KMase K: Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease. Arzneimittelforschung 35:7A118911921985

    • Search Google Scholar
    • Export Citation
  • 50

    Yoshimoto TShirasaka TFujimoto SYoshidumi TYamauchi TTokuda K: Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 49:2352412009

    • Search Google Scholar
    • Export Citation
TrendMD
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 608 574 21
Full Text Views 281 160 17
PDF Downloads 225 124 12
EPUB Downloads 0 0 0
PubMed
Google Scholar